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Conventional DCs (cDCs) play well estab-
lished roles in the induction of immunity and 
tolerance. Both functions require antigen (Ag)-
specific interactions between T cells and cDCs 
in secondary lymphoid tissues. The outcome of 
these interactions depends on the modulation 
and  integration  of  three  signals:  TCR  en-
gagement by peptide–MHC complexes, the   
recruitment  of  costimulatory  and  adhesion 
molecules, and the delivery of soluble media-
tors (Lebedeva et al., 2005). Under steady-state 
conditions,  cDCs  reside  in  peripheral  tissues 
and  lymphoid  organs  in  an  immature  state 
characterized by low cell surface expression of 
MHC class II (MHCII), costimulatory, and ad-
hesion molecules. Immature cDCs continu-
ously  capture  and  present  self-Ags,  circulate 
from tissues to lymphoid organs, and maintain 
tolerance by inducing the deletion of autoreac-
tive T cells or the development of regulatory   
T  cells  (T  reg  cells;  Steinman  et  al.,  2003).   
Signals associated with inflammation, infections, 
or tissue damage induce cDC maturation, a pro-
cess  involving  complex  phenotypical  changes, 
including the up-regulation of MHCII, co-
stimulatory, and adhesion molecules, the se-
cretion of inflammatory mediators, and altered 
migratory  properties.  Activation  of  naive   
T cells by mature cDCs results in clonal ex-
pansion and differentiation into effector and 
memory T cells.
Plasmacytoid DCs (pDCs) constitute a unique 
DC subtype found mainly in the blood and sec-
ondary lymphoid organs. The activation of pDCs 
by infections triggers the secretion of large quan-
tities of type I IFN, suggesting that they have   
crucial innate functions (Colonna et al., 2004). 
However, pDCs also express MHCII molecules 
and undergo a maturation process similar to that 
of  cDCs  (Villadangos  and  Young,  2008).   
Furthermore, pDCs can internalize, process, and 
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Although plasmacytoid dendritic cells (pDCs) express major histocompatibility complex  
class II (MHCII) molecules, and can capture, process, and present antigens (Ags), direct 
demonstrations that they function as professional Ag-presenting cells (APCs) in vivo during 
ongoing immune responses remain lacking. We demonstrate that mice exhibiting a selective 
abrogation of MHCII expression by pDCs develop exacerbated experimental autoimmune 
encephalomyelitis (EAE) as a consequence of enhanced priming of encephalitogenic CD4+  
T cell responses in secondary lymphoid tissues. After EAE induction, pDCs are recruited to 
lymph nodes and establish MHCII-dependent myelin-Ag–specific contacts with CD4+ T cells. 
These interactions promote the selective expansion of myelin-Ag–specific natural regulatory 
T cells that dampen the autoimmune T cell response. pDCs thus function as APCs during the 
course of EAE and confer a natural protection against autoimmune disease development 
that is mediated directly by their ability to present of Ags to CD4+ T cells in vivo.
© 2010 Irla et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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ablation  of  pDCs, 
they could not dis-
criminate  between 
innate  and  adaptive 
functions of these cells. It therefore remained unknown if pDCs 
function as tolerogenic APCs in these systems.
We have investigated whether MHCII-mediated Ag pre-
sentation by pDCs instructs CD4+ T cell responses during 
EAE, a mouse model for multiple sclerosis (MS; Wekerle, 
2008). EAE induced by immunization with myelin oligoden-
drocyte glycoprotein (MOG) was found to be severely exac-
erbated in mice exhibiting a selective abrogation of MHCII 
expression by pDCs. Conversely, EAE was dampened by the 
adoptive transfer of WT, but not MHCII-deficient, pDCs. 
EAE induction triggered the recruitment of pDCs to LNs, 
where they engaged in MHCII-dependent and MOG-specific 
interactions with CD4+ T cells. This inhibited the development 
of pathogenic T cells during the priming phase of the disease 
present Ags to CD4+ T cells and cross-present Ags to CD8+  
T cells (Hoeffel et al., 2007; Sapoznikov et al., 2007; Di Pucchio 
et al., 2008; Young et al., 2008). These findings had suggested 
that pDCs can function as APCs. However, whether pDCs   
indeed  function  as  APCs  in  vivo  during  ongoing  immune   
responses,  and  whether  this  promotes  T  cell–mediated   
immunity and/or the maintenance of self-tolerance, remained   
unsolved issues.
pDCs can participate in the maintenance of peripheral toler-
ance. The induction of T reg cells by pDCs was shown to confer 
tolerance to cardiac allografts, prevent asthmatic reactions to in-
haled Ags, and protect against graft versus host disease (de Heer 
et al., 2004; Ochando et al., 2006; Hadeiba et al., 2008). pDCs 
can also induce tolerance by promoting deletion of pathogenic 
T cells (Goubier et al., 2008) or inhibiting effector CD4+ T cell 
responses in a relapsing model of experimental autoimmune 
encephalomyelitis (EAE; Bailey-Bucktrout et al., 2008). 
As  these  studies  relied  mainly  on  antibody-mediated   
Figure 1.  EAE is exacerbated in mice 
lacking MHCII expression by pDCs. (A) LN 
cells from WT:WT and pIII+IV/:WT chimeras 
and control WT and pIII+IV/ mice were 
analyzed by flow cytometry for the presence 
of CD4+ T cells. Percentages of CD4+ T cells are 
indicated. Results are representative of 10 
experiments, each with at least three mice per 
group. (B) MHCII (I-Ab) expression by LN cDCs, 
B cells, and pDCs was analyzed by flow cy-
tometry for pIII+IV/:WT, H2-Aa/:WT, and 
WT:WT chimeras. Results are representative of 
five experiments, each with at least three mice 
per group. (C) EAE was induced by immuniza-
tion with MOG35–55+CFA in pIII+IV/:WT  
(n = 8), µMT:WT (n = 6), and WT:WT (n = 6) 
chimeras. Results are representative of three 
experiments. The means and SEM are shown. 
ns, not significant; *, P < 0.05; **, P < 0.01;  
***, P < 0.001. (D) LN cells from WT:WT, µMT:WT, 
and µMTxpIII+IV/:WT chimeras were ana-
lyzed by flow cytometry for the expression of 
CD11c and B220. The percentages of B220+  
B cells, CD11chi cDCs, and CD11cintB220+ pDCs 
are indicated. Results are representative of 
three experiments, each with at least three 
mice per group. (E) MHCII (I-Ab) expression by 
LN cDCs and pDCs was analyzed by flow 
cytometry for µMT:WT, µMTxpIII+IV/:WT, 
and WT:WT chimeras. Results are representa-
tive of three experiments, each with at least 
three mice per group. (F) EAE was induced by  
immunization with MOG35–55+CFA in 
µMTxpIII+IV/:WT and µMT:WT chimeras. 
Results are representative of two experiments. 
The means and SEM derived from six mice  
per group are shown. **, P < 0.01; *, P < 0.05. 
(G) pDCs from WT, pIII+IV/, and H2-Aa/ 
mice were incubated with MOG35–55 and trans-
ferred into WT recipients. EAE was induced 1 d 
after the transfer by immunization with 
MOG35–55. Results are representative of two 
independent experiments. The means and SEM 
derived from five mice per group are shown.  
**, P < 0.01; *, P < 0.05.JEM VOL. 207, August 30, 2010 
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generated BM chimeras in which irradiated WT mice were 
reconstituted with BM from pIII+IV/ mice. Normal per-
centages of CD4+ T cells were restored in the LNs and blood 
of pIII+IV/:WT chimeras compared with WT:WT con-
trol chimeras (Fig. 1 A and not depicted). MHCII expression 
by pDCs and B cells remained as negative in pIII+IV/:WT 
chimeras as in H2-Aa/:WT controls (Fig. 1 B and not de-
picted). In contrast, cDCs exhibited WT levels of MHCII ex-
pression in pIII+IV/:WT chimeras (Fig. 1 B). pIII+IV/:
WT chimeras thus differ from WT:WT controls exclusively 
with respect to MHCII expression by pDCs and B cells.
Exacerbation of EAE in mice lacking MHCII expression by pDCs
EAE was induced in pIII+IV/:WT and WT:WT chimeras 
by immunization with MOG35–55 peptide in the presence of 
CFA. EAE induction did not restore MHCII expression by 
pDCs and B cells in pIII+IV/:WT chimeras (Fig. S3 A). 
Disease onset was significantly accelerated and clinical symp-
toms were markedly aggravated in pIII+IV/:WT chimeras 
relative to WT:WT controls. (Fig. 1 C and Table I).
2 d after EAE induction, pDCs in pIII+IV/:WT and 
WT:WT chimeras expressed similarly levels of IFN-4 mRNA 
(Fig. S3 B). After 14 d, pDCs in pIII+IV/:WT chimeras ex-
hibited a twofold increase in IFN-4 mRNA relative to pDCs 
in WT:WT chimeras (Fig. S3 B). However, this modest in-
crease was probably an indirect consequence of the strongly en-
hanced inflammation and exacerbated disease observed at this 
time point (Fig. 1 C; Table I; and see Fig. 3, C–F) because nei-
ther CIITA-deficient nor MHCII-deficient pDCs exhibited 
intrinsic alterations with respect to IFN-4 production (Fig. S2). 
Moreover, EAE development in WT mice was not significantly 
affected by the injection of a dose of IFN- (5 ng) that corre-
sponds to the serum concentration detected in mice with EAE 
(Isaksson et al., 2009) or a 10-fold greater dose (50 ng) that 
boosts the serum concentration to the high levels induced by   
viral infections (Fig. S3 C). These results suggested that EAE   
exacerbation in pIII+IV/:WT chimeras cannot be accounted 
for by the slight increase in IFN- production by pDCs.
To investigate the respective contributions of Ag presen-
tation of pDCs and B cells, we performed EAE experiments 
with µMT:WT chimeras, which lack B cells (Hjelmström et al., 
1998; Fig. 1 D) but exhibit normal MHCII expression by pDCs 
(Fig. 1 E). In marked contrast to pIII+IV/:WT chimeras, 
EAE was not accelerated or aggravated at peak disease in µMT:
WT chimeras (Fig. 1 C and Table I). In accordance with previ-
ous studies (Fillatreau et al., 2002; Lampropoulou et al., 2008; 
by promoting the selective expansion of natural T reg cells. 
Our results demonstrate that Ag-presentation by pDCs can 
inhibit T cell–mediated autoimmunity and can thus deter-
mine the outcome of adaptive immune responses in vivo.
RESULTS
Generation of mice lacking MHCII expression  
by pDCs and B cells
The gene encoding the MHCII transactivator (CIITA), which 
regulates  all  qualitative  and  quantitative  aspects  of  MHCII   
expression, is controlled by three cell type–specific promoters 
called pI, pIII, and pIV (Reith et al., 2005) (Fig. S1 A).   
pI drives CIITA expression in macrophages, microglial cells, 
and all cDC subsets. pIII drives CIITA expression in pDCs and   
B cells. pIV is essential for CIITA expression in thymic epithelial 
cells (TECs) and cells of nonhematopoietic origin stimulated 
with IFN-. The differential dependence of cDCs and pDCs 
on pI and pIII allowed us to use mice lacking pIII and pIV 
(pIII+IV/; LeibundGut-Landmann et al., 2004) to study the 
role of MHCII-restricted Ag presentation by pDCs.
MHCII expression was analyzed by flow cytometry on 
cDCs (CD11chiB220), pDCs (CD11cintB220+PDCA-1+), and 
B cells (CD11cB220+) isolated from LNs of WT, pIII+IV/, 
and MHCII-deficient (H2-Aa/) mice (Fig. S1, B and C). 
MHCII expression by pDCs and B cells was abrogated   
in pIII+IV/ mice to levels similar to those observed in   
H2-Aa/  mice.  Conversely,  cDCs  retained  WT  levels  of 
MHCII expression in pIII+IV/ mice.
Similar levels of IFN-4 mRNA expression and IFN-4 
secretion were induced in vivo in WT and pIII+IV/ mice 
in response to viral infection (Fig. S2 A). Furthermore, ex vivo 
LN pDCs from WT, pIII+IV/, and H2-Aa/ mice pro-
duced equivalent amounts of IFN-4 in response to in vitro 
stimulation with CpG-A (Fig. S2 B). The latter result was   
confirmed using BM-derived pDCs (BM-pDCs; Fig. S2 C).   
In addition, activated BM-pDCs from WT, pIII+IV/, and 
H2-Aa/ mice produced similar amounts of IL-6 and TNF 
(Fig. S2 C) and failed to secrete detectable levels of IL-12, 
IL-10, and MCP-1 (not depicted). These results indicated that 
neither the deficiency in CIITA nor the absence of MHCII 
expression led to intrinsic defects in the production of type I 
IFN or other cytokines by pDCs.
pIV  drives  CIITA  expression  in  cortical  TECs  and   
is hence required for positive selection of CD4+ T cells 
(Waldburger et al., 2003; Irla et al., 2008). pIII+IV/ mice 
therefore lack CD4+ T cells. To circumvent this defect, we 
Table I.  Increased incidence of clinical EAE at early time points in mice lacking MHCII expression by pDCs and B cells
Chimeras Day 12 Day 16 Day 20 Day 24
WT:WT 0/6 (0%) 2/6 (33%) 4/6 (67%) 6/6 (100%)
pIII+IV/:WT 5/8 (62%), *** 8/8 (100%), *** 8/8 (100%), ** 8/8 (100%), NA
µMT:WT 0/6 (0%), NA 1/6 (17%), ns 4/6 (67%), ns 5/6 (83%), ns
EAE was induced by immunization with MOG35–55+CFA in WT:WT, pIII+IV/:WT, and µMT:WT chimeras. The numbers and percentages of mice that developed disease at days 12, 16, 
20, and 24 are provided. P-values for disease incidence were calculated relative to WT:WT mice using the 2 test. ns, not significant; **, P < 0.01; ***, P < 0.001; NA, not applicable.1894 MHCII-mediated Ag presentation by pDC inhibits EAE | Irla et al.
We next performed pDC transfer experiments to 
demonstrate that MHCII expression by pDCs confers 
protection against EAE. MOG35–55-loaded BM-pDCs 
from WT, pIII+IV/, or H2-Aa/ mice were trans-
fered into WT mice 1 d before EAE induction. EAE 
was significantly dampened in mice that had received 
WT pDCs (Fig. 1 G). In contrast, no improvement 
was observed in mice that had received pIII+IV/ or 
H2-Aa/ pDCs (Fig. 1 G). pDC-mediated protection 
against EAE is thus dependent on their expression of 
MHCII molecules.
To confirm that pDCs indeed function as APCs dur-
ing EAE, we induced the disease with MOG protein 
rather than MOG35–55 peptide. EAE induced with MOG 
protein was significantly exacerbated in pIII+IV/:WT 
chimeras compared with WT:WT controls (Fig. S3 D),   
indicating that MHCII-sufficient pDCs can attenuate 
disease severity by capturing, processing, and present-
ing myelin Ags in vivo.
Enhanced infiltration of the central nervous system (CNS) 
by MOG-specific CD4+ T cells in mice lacking MHCII 
expression by pDCs
Histological examinations of the spinal cord (SC) performed 
25 d after induction of EAE revealed that disease exacerba-
tion in pIII+IV/:WT chimeras correlated with increased 
numbers of demyelinated areas (Fig. S4 A), inflammatory foci 
(Fig. S4 B), and infiltrating CD3+ T cells (Fig. S4 C). Flow 
cytometry experiments confirmed that absolute numbers of 
infiltrating cells were markedly increased in pIII+IV/:WT 
chimeras (Fig. 2 A). The percentages of infiltrating cells cor-
responding to cDCs and pDCs were very similar between 
pIII+IV/:WT and WT:WT chimeras (Fig. 2 B). Infiltrat-
ing CD8+ T cells were scarce, and their frequency was in-
creased only modestly in pIII+IV/:WT chimeras (Fig. 2 C). 
In contrast, the percentage of infiltrating CD4+ T cells was 
Matsushita et al., 2008), µMT:WT chimeras did exhibit a sig-
nificant aggravation of the disease during the recovery phase   
(Fig. 1 C). However, this effect was minor compared with the 
dramatically altered disease course observed in pIII+IV/:WT 
chimeras, suggesting that the latter was a consequence of defi-
cient MHCII expression by pDC rather than B cells. These re-
sults nevertheless needed to be interpreted with caution because 
MHCII-deficient B cells remained present in pIII+IV/:WT 
chimeras, whereas B cells were absent in µMT:WT chimeras. 
We therefore generated µMTxpIII+IV/ mice and compared 
EAE development between µMTxpIII+IV/:WT and µMT:
WT chimeras, which both lack B cells (Fig. 1 D) and differ only 
with respect to MHCII expression by pDCs (Fig. 1 E). EAE was 
markedly accelerated and aggravated in µMTxpIII+IV/:WT 
chimeras compared with µMT:WT chimeras (Fig. 1 F), con-
firming that deficient MHCII expression by pDCs is responsible 
for disease exacerbation.
Figure 2.  SC infiltration by pathogenic MOG35–55–specific CD4+ 
T cells is increased in mice lacking MHCII expression by pDCs. EAE 
was induced in WT:WT and pIII+IV/:WT chimeras, and cells infiltrat-
ing the SCs were harvested after 25 d. (A) Absolute numbers of total 
SC-infiltrating cells. (B) The percentages of SC-infiltrating cells cor-
responding to cDCs and pDCs were quantified by flow cytometry.  
(C) Representative flow cytometry profiles and histograms representing 
the percentages of SC-infiltrating CD4+ and CD8+ T cells are shown.  
(D) SC-infiltrating cells were restimulated in vitro with MOG35–55, and 
CD4+ T cells expressing IFN- and IL-17 were quantified by flow cy-
tometry. Representative flow cytometry profiles and histograms repre-
senting the percentages of CD4+ T cells expressing IFN- and IL-17 are 
shown. (E) Secretion of IFN- and IL-17 into the culture supernatant 
was quantified for MOG35–55-restimulated SC-infiltrating cells. (F) CD4+  
T cells expressing CD25 and Foxp3 were quantified by flow cytometry 
in SC-infiltrating cells. Representative flow cytometry profiles and a 
histogram representing the percentages of CD4+ T cells expressing 
Foxp3 are shown. Bar graphs show the means and SEM derived from 
two independent experiments, each with at least three mice per group. 
ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 207, August 30, 2010 
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the  percentage  of  SC-infiltrating  CD4+  
T cells corresponding to T reg cells was re-
duced  in  µMTxpIII+IV/:WT  chimeras 
relative to µMT:WT controls (Fig. S5 E).
Enhanced  infiltration  of  the  SC  by  pathogenic  CD4+  
T cells could not be attributed to altered MHCII expression 
by microglial cells, which up-regulated MHCII expression 
equally during EAE in pIII+IV/:WT and WT:WT chime-
ras (Fig. S6). This is consistent with the fact that CIITA ex-
pression in microglia relies on promoter pI of the CIITA gene 
(Suter et al., 2000; Reith et al., 2005).
Collectively, these results indicated that EAE exacerba-
tion in mice lacking MHCII expression by pDCs correlates 
mainly with strongly increased infiltration of the CNS by 
MOG35–55-specific Th1 and Th17 cells. The latter is consis-
tent with the fact that Th1 and Th17 cells are believed to be 
the major pathogenic cells in EAE (Steinman et al., 2002; 
Murphy et al., 2003; Langrish et al., 2005).
Enhanced priming of encephalitogenic CD4+ T cells in mice 
lacking MHCII expression by pDCs
Adoptive transfer EAE experiments were performed to dis-
criminate between potential roles of MHCII expression by 
pDCs during the effector phase in the CNS and the priming 
phase in secondary lymphoid tissues. To study the contribution 
markedly increased in pIII+IV/:WT chimeras (Fig. 2 C). 
In vitro restimulation assays using exogenous MOG35–55-
loaded APCs indicated that the SC-infiltrating CD4+ T cells 
contained increased numbers of MOG35–55-specific effector 
cells expressing IFN- or IL-17 (Fig. 2 D). The concentra-
tions of these cytokines were consequently increased in the 
culture supernatants of MOG35–55-restimulated T cells iso-
lated from the SCs of pIII+IV/:WT chimeras (Fig. 2 E). 
Similar results were obtained when the restimulation assays 
were repeated with total SC cells containing endogenous 
APCs (unpublished data).
Enhanced cellular inflammation (Fig. S5 A) and increased 
numbers of CD4+ T cells (Fig. S5 B) were also observed in   
the SCs of µMTxpIII+IV/:WT chimeras compared with 
µMT:WT controls. CD4+ T cells isolated from the SCs of 
µMTxpIII+IV/:WT  chimeras  secreted  more  IFN-  and   
IL-17 in response to in vitro restimulation with MOG35–55 
(Fig. S5, C and D).
The fraction of SC-infiltrating CD4+ T cells corresponding 
to Foxp3+ T reg cells tended to be reduced in pIII+IV/:WT 
chimeras compared with WT:WT controls (Fig. 2 F). Similarly, 
Figure 3.  Priming of pathogenic MOG35–55-
specific CD4+ T cells is increased in LNs of mice 
lacking MHCII expression by pDCs. (A) Effector 
MOG35–55-specific CD4+ T cells were generated from 
2D2 mice and adoptively transferred into WT:WT and 
pIII+IV/:WT chimeras. Results are representative of 
two experiments. The means and SEM derived from 
four mice per group are shown. (B) Effector MOG35–55-
specific CD4+ T cells were generated from MOG35–55-
immunized WT:WT or pIII+IV/:WT chimeras and 
adoptively transferred into WT mice. Results show the 
mean and SEM derived from two experiments with a 
total of seven or eight mice per group. *, P < 0.05.  
(C–E) EAE was induced by immunization with  
MOG35–55+CFA in WT:WT and pIII+IV/:WT chimeras. 
dLN cells isolated 9 and 14 d after immunization were 
restimulated in vitro with MOG35–55 and analyzed by 
flow cytometry for the expression of CD4, IFN-, and 
IL-17. (C) Representative flow cytometry profiles ana-
lyzing IFN- and IL-17 expression by CD4+ T cells are 
shown. Percentages of CD4+ T cells expressing IFN- 
and IL-17 are indicated. (D and E) Histograms repre-
sent the percentages of CD4+ T cells expressing IFN- (D) 
or IL-17 (E). Results show the mean and SEM  
derived from two independent experiments with at 
least three mice per group. *, P < 0.05; **, P < 0.01.  
(F) Concentrations of IFN-, IL-17, IL-4, and IL-10 
were measured in culture supernatants from  
MOG35–55-restimulated LN cells isolated 14 d after 
induction of EAE. Results show the means and SEM 
derived from two independent experiments, each with 
at least three mice per group. ns, not significant;  
*, P < 0.05; **, P < 0.01.1896 MHCII-mediated Ag presentation by pDC inhibits EAE | Irla et al.
transferred into WT recipients. Mice that had re-
ceived CD4+ T cells from the pIII+IV/:WT 
chimeras developed EAE with an earlier onset and 
increased severity (Fig. 3 B). These results sug-
gested that MHCII expression by pDCs confers protection 
against EAE by inhibiting the priming of encephalitogenic   
T cells in secondary lymphoid tissues but has no evident im-
pact on the subsequent effector phase in the CNS.
In vitro T cell restimulation assays were next used to 
measure the frequencies of MOG35–55-specific IFN-– and 
IL-17–secreting CD4+ T cells in the LNs of WT:WT and 
pIII+IV/:WT chimeras at days 9 and 14 after EAE induc-
tion.  At  both  time  points,  IFN-–  and  IL-17–secreting 
MOG35–55-specific CD4+ T cells were significantly more 
of  MHCII  expression  by  pDCs  during  the  effector  phase, 
MOG35–55-specific  CD4+  T  cells  isolated  from  2D2  TCR 
transgenic mice were activated in vitro with MOG35–55-loaded 
APCs and transferred into pIII+IV/:WT and WT:WT chi-
meras. The incidence, time course, and severity of EAE were 
indistinguishable between the pIII+IV/:WT and WT:WT 
recipients (Fig. 3 A). To study the contribution of MHCII ex-
pression by pDCs to encephalitogenic T cell priming, equal 
numbers of CD4+ T cells purified from the LNs of MOG35–55- 
immunized  pIII+IV/:WT  and  WT:WT  chimeras  were 
Figure 4.  pDCs recruited to LNs during EAE establish 
Ag-specific interactions with CD4+ T cells. (A) WT and 
pIII+IV/ mice were injected with CFA and dLNs were har-
vested after 2 d. dLN sections from untreated and CFA-
treated mice were stained with antibodies against PNAd to 
label HEVs and PDCA-1 to label pDCs. Histograms show the 
density (percentage of surface) of pDCs in regions situated 
near to (<20 µm) or distant from (>20 µm) HEVs. Results are 
representative of three independent experiments. The means 
and SEM derived from three independent mice per group  
are shown. ns, not significant; *, P < 0.05; **, P < 0.01. 7–12 
confocal images were analyzed for each genotype and re-
gion. Representative images are shown. (B) CMTMR-labeled 
2D2 CD4+ T cells were adoptively transferred into WT and 
pIII+IV/ mice that had been injected 1 d previously with 
MOG35–55+CFA or CFA alone. dLNs were harvested 1 d after 
the T cell transfer, and sections were stained with antibodies 
against PDCA-1. Histograms show the percentages of 2D2  
T cells that interact with pDCs and show the mean and SEM 
derived from at least two independent experiments. ns, not 
significant; *, P < 0.05; ***, P < 0.001. The numbers of confocal 
images analyzed (N) are indicated at the bottom of each  
bar. The ratios above the bars represent the number of inter-
acting 2D2 T cells over the total number of 2D2 T cells. Repre-
sentative images are shown for MOG35–55+CFA-treated WT 
and pIII+IV/ mice. Arrowheads indicate 2D2 T cells that 
interact with pDCs. (C and D) CMTMR-labeled 2D2 or OT-II  
T cells were adoptively transferred into WT:WT and pIII+IV/:
WT chimeras that had been immunized 1 d previously with 
MOG35–55+CFA. dLNs were harvested 1 d after the T cell 
transfer, and sections were stained with antibodies against 
PDCA-1. (C) The histogram shows the percentages of 2D2 or 
OT-II T cell that interact with pDCs and shows the mean and 
SEM derived from at least two independent experiments.  
***, P < 0.001; ns, not significant. The numbers of confocal 
images analyzed (N) are indicated at the bottom of each bar. 
The ratios above the bars represent the number of interact-
ing CD4+ T cells over the total number of CD4+ T cells. Rep-
resentative images from WT:WT and pIII+IV/:WT chimeras 
are shown. Arrowheads indicate 2D2 T cells interacting with 
pDCs. (D) The histogram shows the distribution of pDCs in 
contact with one, two, three, or four 2D2 T cells. The num-
bers of pDCs that were analyzed are indicated above the 
bars. A representative image of a pDC interacting with three 
different 2D2 T cells in the LN of a WT:WT chimera is shown.JEM VOL. 207, August 30, 2010 
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frequency observed for the irrelevant OT-II T cells (Fig. 4 C). 
Finally, the proportion of pDCs that interact with multiple 2D2 
T cells was higher in WT:WT chimeras than in pIII+IV/:
WT chimeras (Fig. 4 D). pDCs interacting with multiple OT-II 
T cells were not observed in either WT:WT or pIII+IV/:
WT chimeras (unpublished data). Collectively, these results sug-
gested that induction of EAE leads to recruitment of pDCs to 
the dLNs, where they localize preferentially around HEVs and 
establish Ag-specific and MHCII-dependent interactions with 
MOG35–55-specific CD4+ T cells.
frequent in pIII+IV/:WT chimeras (Fig. 3, C–E). The 
concentrations of IFN- and IL-17 were also greater in   
the culture supernatants of restimulated T cells from the 
pIII+IV/:WT chimeras (Fig. 3 F). In contrast, IL-4 pro-
duction was low and not significantly affected. Enhanced 
MOG35–55-specific Th1 and Th17 development in pIII+IV/:
WT chimeras was therefore not associated with an impaired 
Th2 response. Interestingly, a decrease in the immunosup-
pressive cytokine IL-10 was detected in the culture superna-
tants  of  T  cells  isolated  from  pIII+IV/:WT  chimeras 
(Fig. 3 F). These results suggested that MHCII expression by 
pDCs attenuates the priming of encephalitogenic Th1 and 
Th17 CD4+ T cells, possibly through a mechanism impli-
cating IL-10–dependent inhibition.
pDCs recruited to LNs during EAE engage in Ag-specific 
contacts with CD4+ T cells
Staining of sections with antibodies against PDCA-1 indicated 
that  immunization  with  CFA  induced  the  recruitment  of 
pDCs to the T cell zone of the draining LNs (dLNs) within 2 d 
(Fig. 4 A). pDCs were preferentially localized near HEVs in 
both  immunized  and  nonimmunized  mice.  No  significant 
differences in pDC recruitment or localization were observed 
between WT and pIII+IV/ mice (Fig. 4 A). To assess the 
ability of these pDCs to establish Ag-specific contacts with 
CD4+ T cells, MOG35–55-specific CD4+ T cells purified from 
2D2 mice were labeled with CMTMR and transferred into 
WT or pIII+IV/ mice that had been immunized 1 d previ-
ously with MOG35–55+CFA or CFA alone. Contacts between 
the 2D2 T cells and PDCA-1+ pDCs were quantified in dLN 
sections 24 h after the transfer. 26.9 ± 2.4% of the 2D2 T cells 
were found in close proximity to pDCs in the dLNs of 
MOG35–55+CFA–immunized WT mice, whereas this fraction 
was  only  4.9  ±  1.3%  in  the  dLNs  of  MOG35–55+CFA– 
immunized pIII+IV/ mice (Fig. 4 B). Furthermore, only 
10.2 ± 1.9% of the 2D2 T cells interacted with pDCs in the 
dLNs of WT mice injected with CFA alone. These results indi-
cated that pDCs recruited to the dLNs during EAE establish 
frequent contacts with 2D2 T cells in a MOG35–55–specific and 
MHCII-dependent manner. In mice injected with CFA alone,   
significantly more 2D2 T cells were found close to pDCs in 
WT mice (10.2 ± 1.9%) than in pIII+IV/ mice (4.4 ± 1.2%), 
suggesting that the 2D2 T cells scan pDCs for the presence of 
their cognate MHCII–Ag complexes (Fig. 4 B).
The establishment of Ag-specific and MHCII-dependent 
contacts between pDCs and 2D2 T cells in the dLNs during 
EAE was next documented using pIII+IV/:WT and WT:WT 
chimeras.  CMTMR-labeled  2D2  T  cells  or  control  OT-II   
T cells were transferred into the chimeras after the induction of 
EAE by immunization with MOG35–55. A strong recruitment of 
pDCs to the dLNs was again observed 48 h after immuniza-
tion (unpublished data). The frequency of MOG35–55-specific 
2D2 T cells that interacted with pDCs was fivefold higher in 
WT:WT chimeras (15.1 ± 1.3%) than in pIII+IV/:WT chi-
meras (3.5 ± 0.6%; Fig. 4 C). The frequency of 2D2 T cells in-
teracting with WT:WT pDCs was significantly higher than the   
Figure 5.  pDCs present MOG35–55 during EAE. (A and B) LN cells  
were pooled from 8–10 WT and pIII+IV/ mice that had been immunized 
2 d previously with MOG35–55+CFA or CFA alone. The cells were then 
stained with antibodies against CD19, CD11c, and B220, and cDCs 
(CD19CD11chiB220 cells) and pDCs (CD19CD11cintB220+ cells) were 
purified by sorting. (A) Representative flow cytometry profiles are shown 
to illustrate the labeling and purification of pDCs and cDCs. (B) Variable 
numbers of purified cDCs and pDCs were incubated for 18 h with 2D2  
T cells. The percentages of activated CD69hi CD4+ 2D2 T cells were then 
quantified by flow cytometry. Results are representative of two experi-
ments. The graph shows the means and SEM derived from two experi-
ments. (C) MHCII (I-Ab), CD86, and CD40 expression was analyzed by flow 
cytometry on cDCs and pDCs isolated from the dLNs of WT mice that had 
been immunized 2 d previously with MOG35–55+CFA. cDCs and pDCs iso-
lated from the LNs of nonimmunized WT mice (day 0) were used as con-
trols. The histograms represent the mean fluorescence intensity (mfi) and 
SEM derived from two experiments.1898 MHCII-mediated Ag presentation by pDC inhibits EAE | Irla et al.
pDCs can thus indeed function as compe-
tent  APCs  that  present  MOG35–55  in  vivo 
during EAE.
Impaired T reg cell expansion during EAE  
in mice lacking MHCII expression by pDCs
The finding that MHCII-mediated Ag pre-
sentation by pDCs inhibits encephalitogenic CD4+ T cell   
responses during EAE suggested that pDCs might promote   
the development of CD4+ T reg cells. T reg cell populations 
were therefore analyzed in naive and MOG35–55-immunized 
pIII+IV/:WT and WT:WT chimeras. The frequency of 
Foxp3+ T reg cells in total LN CD4+ T cells was identical   
between  naive  pIII+IV/:WT  and  WT:WT  chimeras 
(Fig. 6 A). This was also true for Foxp3+ T reg cells in blood 
(Fig. S7A). 14 d after the induction of EAE, the percentage of 
T reg cells increased to an equal extent in pIII+IV/:WT and 
WT:WT chimeras (Fig. 6 A). The absence of MHCII expres-
sion by pDCs, therefore, did not have a major impact on total 
T reg cell frequencies.
Proliferation in the Foxp3+ CD4+ T reg cell population 
was quantified by analyzing the expression of Ki67 (Gerdes   
et al., 1984). No difference in the frequency of proliferating   
pDCs function as APCs during EAE
To confirm that pDCs present MOG35–55 during EAE, they 
were purified from the dLNs of WT and pIII+IV/ mice 48 h 
after immunization with MOG35–55+CFA (Fig. 5 A). cDCs 
were purified in parrallel. Variable numbers of pDCs and cDCs 
were incubated with MOG35–55-specific 2D2 T cells and T cell 
activation was measured by examining the expression of CD69 
(Fig. 5 B). cDCs from WT and pIII+IV/ mice activated 2D2 
T cells with equal efficiency. pDCs from WT mice activated 
2D2 T cells as efficiently as cDCs. In contrast, pDCs from 
pIII+IV/ mice were unable to induce 2D2 T cell activation 
above the background level observed for DCs isolated from 
mice immunized with CFA alone. In agreement with their abil-
ity to function as efficient APCs, dLN pDCs isolated from WT 
mice 2 d after EAE induction up-regulated MHCII, CD86, and 
CD40 expression in a manner similar to that of cDCs (Fig. 5 C). 
Figure 6.  Defective T reg cell proliferation in 
mice lacking MHCII expression pDCs. (A–C) WT:WT 
and pIII+IV/:WT chimeras were immunized with 
MOG35–55+CFA. Nonimmunized (naive) chimeras were 
used as controls. dLNs were harvested 14 d later and 
analyzed by flow cytometry. (A) CD25 and Foxp3 ex-
pression by CD4+ T cells was analyzed. Representative 
flow cytometry profiles are shown, with percentages 
of Foxp3+ T reg cells indicated. The histogram shows 
the means and SEM derived from three experiments, 
each with three mice per group. ns, not significant. 
(B) Frequencies of proliferating Ki67+ cells were de-
termined in the Foxp3+ CD4+ T reg cell population. 
Representative flow cytometry profiles are shown, 
with percentages of Ki67+ T reg cells indicated. The 
Ki67+ gate was defined relative to staining with an 
isotype control. The histogram shows the means  
and SEM derived from three experiments, each with 
three mice per group. **, P < 0.01. (C) Frequencies of 
proliferating Ki67+ cells were determined in the 
CD25Foxp3 (non–T reg cell) CD4+ T cell population. 
Representative flow cytometry profiles are shown, 
with percentages of Ki67+ cells indicated. The Ki67+ 
gate was defined relative to staining with an isotype 
control. The histogram shows the means and SEM 
derived from three experiments, each with three mice 
per group. ns, not significant. (D) IL-10 and TGF-1 
mRNA levels were quantified by quantitative RT-PCR 
in CD4+ T cells purified from the dLNs of WT:WT and 
pIII+IV/:WT chimeras 14 d after immunization with 
MOG35–55+CFA. CD4+ T cells purified from LNs of non-
immunized (naive) WT:WT chimeras were used as a 
reference. The means and SEM were derived from 
three to four measurements, each made with three 
mice per group. *, P < 0.05.JEM VOL. 207, August 30, 2010 
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Immunization-induced T reg cell proliferation was also 
impaired in the spleen of pIII+IV/:WT chimeras (Fig. S7 B). 
In contrast, it was not observed in the SCs of pIII+IV/:WT 
chimeras (Fig. S7 C), suggesting that T reg cell restimulation in 
the CNS is mediated by APCs other than pDCs, such as cDCs, 
macrophages or microglia, which retain MHCII expression in 
pIII+IV/:WT chimeras. This experiment also confirmed that 
MHCII-mediated Ag presentation by pDCs does not control   
T cell responses in the CNS.
Proliferating T reg cells are more efficient at suppressing 
T cell responses than resting T reg cells (Klein et al., 2003). 
In agreement with this, IL-10 and TGF-1 mRNA levels in 
CD4+ T cells purified from LNs after EAE induction were 
T reg cells was observed in LNs between naive pIII+IV/:
WT and WT:WT chimeras (Fig. 6 B). As described previ-
ously (Darrasse-Jèze et al., 2009), this homeostatic T reg 
cell proliferation was markedly greater than that of non– 
T reg CD4+ T cells (Fig. 6 C). After immunization with 
MOG35–55, the percentage of proliferating T reg cells in LNs 
increased significantly in WT:WT chimeras but remained 
unchanged in pIII+IV/:WT chimeras (Fig. 6 B). The fre-
quency of proliferating T reg cells in immunized pIII+IV/:
WT mice was not significantly greater than the basal level 
observed in naive mice (Fig. 6 B). The defect in immunization- 
induced proliferation was restricted to T reg cells because 
no difference in proliferation of non–T reg CD4+ T cells 
was observed between pIII+IV/:WT and WT:WT chi-
meras (Fig. 6 C).
Figure 7.  Ag presentation by pDCs induces T reg 
cell development. (A) CD4+ T cells were purified from 
the LNs of 2D2 mice, labeled with CFSE, and transferred 
into WT:WT and pIII+IV/:WT chimeras that had been 
immunized 1 d previously with MOG35–55+CFA. Nonim-
munized WT recipients were used as controls. 3 d after 
transfer, 2D2 T cells in the LNs were analyzed by flow 
cytometry for dilution of CFSE labeling (left and right) 
and the frequency of Foxp3+ cells (right). Percentages 
of cells in the peaks corresponding to divisions 0–7 
(D0–D7) are indicated on the left. Percentages of 
Foxp3+ cells are indicated on the top and right. The 
results are representative of two independent experi-
ments. (B) CD4+ T cells were purified from the LNs of 
2D2 mice, labeled with CFSE, and transferred into  
WT:WT, pIII+IV/:WT, µMT:WT, and µMTxpIII+IV/:WT 
chimeras that had been immunized 1 d previously with 
MOG35–55+CFA. 3 d after transfer, 2D2 T cells in the 
dLNs were analyzed by flow cytometry to determine the 
frequency of Foxp3+ T reg cells. The results are repre-
sentative of two independent experiments. The means 
and SEM were derived from three chimeras per group. 
ns, not significant; *, P < 0.05; **, P < 0.01. (C) CD4+  
T cells were purified from LNs of 2D2 mice, labeled with 
CFSE, and transferred into WT:WT and pIII+IV/:WT 
chimeras that had been immunized 1 d previously with 
MOG35–55+CFA. 3 d after transfer, dLN sections were 
stained using antibodies against PDCA-1 and Foxp3. 
Representative images derived from two independent 
experiments are shown. Arrowheads indicate CFSE+ 
Foxp3+ 2D2 T reg cells; circles indicate CFSE+ Foxp3+ 
2D2 T reg cells that interact with pDCs. (D) The histo-
gram shows the percentages of CFSE+ 2D2 T cells that 
interact with pDCs. The ratios above the bars represent 
the number of interacting 2D2 T cells over the total 
number of 2D2 T cells. (E) The histograms show the 
percentages of Foxp3+ T reg cells among CFSE+ 2D2  
T cells found in close proximity to pDCs. The ratios above 
the bars represent the number of Foxp3+ 2D2 T cells 
over the number of 2D2 T cells interacting with pDCs. 
(D and E) The number of confocal images analyzed (N) 
is indicated at the bottom of each bar. Results were 
pooled from two independent experiments with two 
mice per group. Histograms show the means and SEM 
derived from two independent experiments with two 
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µMT:WT chimeras. The frequency of Foxp3+ T reg cells in 
the proliferating 2D2 T cell population was again reduced 
in  µMTxpIII+IV/:WT  chimeras  relative  to  µMT:WT 
controls (Fig. 7 B), confirming that impaired expansion of 
2D2 T reg cells resulted from the loss of MHCII expression 
by pDCs. B cells appeared to have little or no impact on 
2D2 T reg cell expansion because the frequencies of 2D2   
T reg cells were similar between WT:WT and µMT:WT chi-
meras and between pIII+IV/:WT and µMTxpIII+IV/: 
WT chimeras.
Staining of LN sections at day 3 confirmed that 2D2   
T cells interacted less frequently with pDCs in pIII+IV/:WT 
chimeras than in WT:WT controls (Fig. 7, C and D). Foxp3+ 
cells were also markedly less enriched among 2D2 T cells lo-
cated in close proximity to pDCs in pIII+IV/:WT chime-
ras than in WT:WT controls (Fig. 7, C and E). Finally, the 
frequencies of Foxp3+ 2D2 T cells were globally greater in 
our analysis of LN sections (Fig. 7, D and E) than when they 
were quantified by flow cytometry (Fig. 7, A and B). This   
is consistent with the fact that our analysis of LN sections 
significantly lower in pIII+IV/:WT chimeras than in WT:WT 
controls (Fig. 6 D).
Impaired Ag-specific T reg cell expansion in mice lacking 
MHCII expression by pDCs
Adoptive transfer experiments were performed with CD4+  
T cells purified from 2D2 mice to determine whether impaired 
immunization-induced T reg cell expansion in pIII+IV/:
WT  chimeras  would  affect  MOG35–55-specific  T  reg  cells. 
CD4+ 2D2 T cells were labeled with CFSE and transferred 
into  MOG35–55-immunized  pIII+IV/:WT  and  WT:WT 
chimeras. Naive WT mice were used as control recipients. 
CFSE+ 2D2 T cells present in LNs were analyzed 3 d after 
transfer for their proliferation and expression of Foxp3. 
Although 2D2 T cells did not proliferate in nonimmunized 
mice, they proliferated massively and to a similar extent in im-
munized pIII+IV/:WT and WT:WT chimeras (Fig. 7 A). 
The frequency of Foxp3+ T reg cells within the proliferating 2D2 
T cell population was significantly reduced in pIII+IV/:WT 
chimeras relative to WT:WT controls (Fig. 7, A and B).
To exclude a role of B cells, the 2D2 T cell transfer ex-
periments  were  repeated  with  µMTxpIII+IV/:WT  and 
Figure 8.  pDCs promote the selective  
expansion of natural T reg cells. (A and B) BM pDCs 
(CD11cintB220+PDCA-1+) or BM cDCs (CD11chiB220PDCA-1) 
were isolated from WT mice, loaded with MOG35–55 and  
activated with CpG-A plus CpG-B or LPS, respectively. The 
DCs were then used to stimulate CD4+ T cells isolated from 
2D2 × Foxp3-GFP mice. (A) The frequencies of GFP+ T reg 
cells were analyzed in the CD4+ T cell population after 96 h 
of stimulation. Representative flow cytometry profiles are 
shown, with percentages of GFP+ T reg cells indicated. The 
histogram shows the percentages of GFP+ T reg cells in the 
CD4+ 2D2 T cell population. The means and SEM were de-
rived from three experiments. ***, P < 0.001. (B) Concentra-
tions of IFN- and IL-17 were measured in the culture 
supernatants. The histogram shows the means and SEM 
derived from three experiments. *, P < 0.05. (C) Total or GFP 
CD4+ T cells were purified from 2D2 × Foxp3-GFP CD45.2+ 
donors (left profiles) and transferred into CD45.1 hosts. The 
recipient mice were immunized 1 d after the transfer with 
MOG35–55+CFA. dLN cells isolated 6 d after the transfer were 
analyzed by flow cytometry for the frequency of CD45.2+ 
2D2 cells in the total CD4+ T cell population (middle profiles) 
and for GFP expression in CD4+CD45.2+ 2D2 T cells (right 
profiles). Zoomed views are shown in the right profiles to 
facilitate visualization of the minor GFP+ T reg cell popula-
tions. The results are representative of two experiments. The 
means and SEM were derived from three mice per group.  
*, P < 0.05. (D) Total or GFP CD4+ T cells were purified from 
Foxp3-GFP CD45.2+ donors (left profiles) and transferred into 
CD45.1 hosts. The recipient mice were immunized 1 d after 
the transfer with MOG35–55+CFA. dLN cells isolated 6 d after 
the transfer were analyzed by flow cytometry for the fre-
quency of CD45.2+ donor cells in the total CD4+ T cell popu-
lation (middle profiles) and for GFP expression in the donor 
CD4+CD45.2+ T cells (right profiles). Zoomed views are shown 
in the right profiles to facilitate visualization of the minor 
GFP+ T reg cell populations. The results are representative of 
two experiments. The means and SEM were derived from 
three mice per group. ***, P < 0.001.JEM VOL. 207, August 30, 2010 
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expansion in response to induction of EAE is due mainly to 
the expansion of preexisting natural T reg cells.
MHCII expression by pDCs is required for the expansion  
of T reg cells capable of inhibiting EAE
T reg cell transfer experiments were performed to determine 
whether disease exacerbation in pIII+IV/:WT chimeras is a 
direct consequence of impaired T reg cell expansion. CD4+ 
CD25+ T reg cells were isolated from the dLNs of MOG35–55-
immunized  WT:WT  or  pIII+IV/:WT  chimeras.  These 
cells, which are predominantly Foxp3+ (Fig. 9 A), were trans-
ferred into WT hosts. EAE was then induced in the recipient 
mice. The transfer of T reg cells derived from immunized 
WT:WT chimeras strongly attenuated EAE severity in the re-
cipients (Fig. 9 B and Table S1). In contrast, the transfer of T reg 
cells derived from immunized pIII+IV/:WT chimeras did 
not alter the disease course (Fig. 9 B and Table S1). MHCII ex-
pression by pDCs is thus required for the generation of sup-
pressive T reg cells capable of attenuating EAE.
DISCUSSION
Although  pDCs  can  capture,  process,  and  present  Ags, 
whether they actually function as APCs capable of shaping 
the outcome of T cell responses in vivo by presenting Ags to 
naive T cells during ongoing adaptive immune responses re-
mained unknown. Studies relying on antibody-mediated de-
pletion of pDCs had indicated that pDCs can stimulate T cell 
priming (Isaksson et al., 2009) or promote the induction of   
T cell tolerance (de Heer et al., 2004; Bailey-Bucktrout et al., 
2008; Jongbloed et al., 2009). However, because these stud-
ies were based on pDC ablation they could not discriminate 
between the contributions of innate and adaptive functions   
of pDCs. Activated pDCs are known to be major sources of 
type I IFNs and other inflammatory cytokines. These soluble 
mediators can have profound impacts on the outcome of T cell 
activation. It was therefore crucial to determine to what extent 
Ag presentation by pDCs influences the outcome of immune 
responses in vivo.
Our study provides several lines of evidence demonstrat-
ing that pDCs function as APCs that regulate the priming 
phase of EAE. First, early after disease onset, LN CD4+ T cells 
from  chimeras  lacking  MHCII  expression  by  pDCs  were 
focused on pDC-rich areas and therefore selected for regions 
enriched in T reg cells retained by contacts with pDCs.
To assess the ability of pDCs to promote MOG35–55- 
specific T reg cell expansion we performed in vitro restimu-
lation assays with 2D2 T cells purified from 2D2 × Foxp3-GFP 
mice and mature MOG35–55-loaded pDCs. MOG35–55-loaded 
cDCs were used as control APCs. The frequency of GFP+  
T reg cells induced in the 2D2 T cell population was mark-
edly greater when pDCs were used as the APCs (Fig. 8 A). 
Conversely, the development of Th1 and Th17 cells, as   
assessed by the secretion of IFN- and IL-17 into the superna-
tant, was markedly greater with cDCs (Fig. 8 B). Collec-
tively, these results support the model that MHCII-mediated 
presentation of MOG35–55 by pDCs favors the expansion of 
MOG35–55-specific T reg cells.
Induction of EAE promotes the expansion of natural T reg cells
T reg cell expansion during EAE could be the result of pro-
liferation of natural T reg cells or differentiation of T reg 
cells from non–T reg cell precursors. To distinguish be-
tween these two possibilities, total or GFP CD4+ T cells 
were purified from 2D2 × Foxp3-GFP CD45.2+ mice and 
transferred into WT CD45.1+ hosts. The recipient mice 
were then immunized with MOG35–55 and 2D2 T cell pop-
ulations were analyzed in the dLNs after 6 d. Both total and 
GFP 2D2 T cells expanded extensively in the immunized 
mice (Fig. 8 C). The frequencies of GFP+ 2D2 T reg cells 
in the immunized mice were significantly greater in recipi-
ents that had received total 2D2 T cells than in those that 
had received GFP 2D2 T cells (Fig. 8 C). This suggested 
that 2D2 T reg cell development resulted from the expan-
sion of preexisting T reg cells rather than from de novo dif-
ferentiation of T reg cells from non–T reg cells. However, 
2D2 T reg cell frequencies in the immunized mice were 
very low, probably as a result of massive proliferation of 
non–T reg 2D2 cells. We therefore repeated the transfer 
experiments with total and GFP polyclonal CD4+ T cells 
from Foxp3-GFP mice. As reported previously using this 
approach (Korn et al., 2007), GFP+ T reg cell frequencies 
were  significantly  higher  in  recipients  that  had  received   
total CD4+ T cells than in those that had received GFP 
CD4+ T cells (Fig. 8 D). This confirmed that T reg cell   
Figure 9.  pDCs promote the expansion of T reg 
cells capable of attenuating EAE. CD4+CD25+ T reg 
cells were purified from the LNs of MOG35–55+CFA-
immunized WT:WT or pIII+IV/:WT chimeras and 
transferred into WT recipients. 1 d after the transfer, 
EAE was induced in the recipients by immunization 
with MOG35–55+CFA. (A) Representative flow cytom-
etry profiles are shown to illustrate the expression of 
CD4, CD25, and Foxp3 by the purified T reg cells. 
Percentages of CD25+ and Foxp3+ cells are indicated. 
(B) Results from two experiments were pooled. The 
means and SEM were derived from at least six mice 
per group. ns, not significant; *, P < 0.05; **, P < 0.01.1902 MHCII-mediated Ag presentation by pDC inhibits EAE | Irla et al.
T reg cells rather than the expansion of T reg cells newly de-
rived from Foxp3CD4+ T cells. Finally, disease exacerbation 
in mice lacking MHCII expression by pDCs was a direct con-
sequence of the impaired induction of a T reg cell population 
capable of suppressing EAE. These results demonstrated that 
MHCII-mediated Ag presentation by pDCs protects against 
the development of EAE by promoting a selective expansion 
of Ag-specific Foxp3+ T reg cells.
The difference in T reg cell proliferation observed be-
tween WT and mutant chimeras did not lead to a difference 
in the frequency of total LN T reg cells. This probably re-
flects the exit of T reg cells from the secondary lymphoid tis-
sues and their migration to the CNS. MOG-specific Foxp3+ 
T reg cells traffic readily to the CNS (Korn et al., 2007). This 
previous study also found that T reg cell numbers did not 
change significantly in peripheral lymphoid compartments 
during EAE. Migration of the newly expanded T reg cells to 
the CNS is also consistent with the finding that the reduction 
in proliferating LN T reg cell numbers in mutant chimeras 
correlates with a decrease in the frequency of T reg cells in-
filtrating the SC.
The frequency of T reg cells infiltrating the SC of mice 
lacking MHCII expression by pDCs was reduced only mod-
estly. Furthermore, in contrast to T reg cells found in the 
spleen and LNs, the frequency of proliferating T reg cells was 
not reduced in the SCs of the mutant chimeras. These obser-
vations could be explained by the fact that T reg cell prolifer-
ation in the CNS can be sustained by Ag restimulation by 
microglial cells (Aloisi, 2001) or infiltrating cDCs and macro-
phages, which retain normal MHCII expression in our mu-
tant chimeras. This would be consistent with previous studies 
showing that these APCs can restimulate encephalitogenic 
CD4+ T cells in the CNS (Wekerle et al., 1987; Greter et al., 
2005; Bailey et al., 2007).
A change in the number and function of MOG-specific 
T reg cells in the CNS has been reported to coincide with 
EAE recovery (Korn et al., 2007). This suggested that TCR 
engagement of myelin-specific T reg cells is required for their 
relocation to the CNS and their reactivation in situ. In agree-
ment with this, we also observed an increase in T reg cells in 
the SC of WT mice during the recovery phase that follows 
peak disease (unpublished data). However, the recruitment 
and activity of T reg cells is unlikely to be under the control 
of Ag presentation by pDCs localized in the CNS because 
our adoptive-transfer experiments indicated that the effector 
phase of EAE is not altered in mice lacking MHCII expres-
sion by pDCs.
Collectively, our results support the model that MHCII-
mediated presentation of myelin Ags by pDCs in secondary 
lymphoid tissues confers natural protection against EAE be-
cause it favors the selective expansion of natural T reg cells 
capable of suppressing the priming and/or expansion of 
pathogenic  IL-17–  and  IFN-–secreting  effector  CD4+  
T cells. It may be relevant that contact duration of in vitro 
interactions between CD4+ T cells and pDCs was found to 
be considerably shorter than for interactions between CD4+ 
markedly enriched in pathogenic MOG35–55-specific IFN-– and   
IL-17–secreting T cells, and these cells exhibited a significantly 
increased capacity to transfer the disease to WT recipients. 
Second, the induction of EAE promoted a rapid recruitment 
of pDCs to LNs, where they concentrated in the vicinity of 
HEVs. Thus, as demonstrated for cDCs (Bajénoff et al., 2003), 
pDCs  recruited  to  the  LNs  are  strategically  positioned  for   
being scanned efficiently by incoming T cells. Third, EAE in-
duction  promoted  the  establishment  of  MHCII-dependent 
and Ag-specific interactions between CD4+ T cells and   
pDCs in LNs. Fourth, LN pDCs purified from MOG35–55- 
immunized mice were as efficient as cDCs in activating 
MOG35–55–specific CD4+ T cells ex vivo in the absence of added 
exogenous MOG35–55 peptide. Fifth, pDCs purified from the 
LNs after induction of EAE exhibited an activated phenotype 
characterized by increased cell surface expression of MHCII 
and T cell costimulatory molecules. The latter is consistent 
with the fact that pDCs can activate T cells efficiently provided 
they undergo maturation (Villadangos and Young, 2008). 
Finally, EAE was exacerbated in chimeras lacking MHCII   
expression by pDCs after active immunization not only with 
MOG35–55 peptide but also with MOG protein, suggesting that 
MHCII-sufficient pDCs can capture, process, and present my-
elin Ags in vivo. Collectively, these results indicate that pDCs 
can function as true APCs in vivo.
Antibody-mediated  depletion  of  pDCs  was  recently   
reported to lead to disease aggravation in EAE (Bailey- 
Bucktrout et al., 2008). Because pDCs were ablated in this 
system, it was not possible to determine whether disease ex-
acerbation was a result of the abrogation of Ag presentation 
by pDCs or if it was a result of altered production of soluble 
mediators such as type I IFNs. We found that WT and MHCII- 
deficient pDCs exhibit similar intrinsic abilities to produce 
type I IFNs and other cytokines. Furthermore, EAE was damp-
ened by the adoptive transfer of WT pDCs but not by MHCII-
deficient pDCs. Lastly, the administration of IFN- did not 
alter the course of EAE. Collectively, these results demonstrate 
that pDCs attenuate EAE by presenting Ags to CD4+ T cells 
rather than via their innate functions.
In naive mice, total T reg cell numbers and frequencies of 
proliferating T reg cells were indistinguishable between WT 
mice and mice lacking MHCII expression by pDCs. As de-
scribed previously (Darrasse-Jèze et al., 2009), this suggests 
that homeostatic proliferation of T reg cells under steady-state 
conditions is dependent on cell types other than pDCs, such 
as cDCs. In contrast to naive mice, a clear increase in T reg 
cell  proliferation  was  evident  upon  EAE  induction  in  the 
spleens and LNs of WT mice compared with mice lacking 
MHCII expression by pDCs. In agreement with a previous 
study demonstrating that actively dividing T reg cells are more 
suppressive than quiescent T reg cells (Klein et al., 2003), im-
paired T reg cell proliferation in chimeras lacking MHCII ex-
pression by pDCs was associated with decreased production   
of suppressive cytokines. As documented by an earlier study 
(Korn et al., 2007), T reg cell proliferation during EAE was 
found to reflect the expansion of preexisting natural Foxp3+  JEM VOL. 207, August 30, 2010 
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Adoptive transfer of T reg cells was performed as follows. Chimeric 
mice were immunized with MOG35–55+CFA, dLNs were harvested after   
10 d, and 2 × 105 purified CD4+CD25+ T cells were injected into the tail 
vein of recipient WT mice. EAE was then induced by immunization of the 
recipients with MOG35–55+CFA.
Adoptive transfer of pDCs was performed as follows. 6 × 105 BM-pDCs 
loaded with MOG35–55 were transferred into WT recipients. EAE was then 
induced by immunization with MOG35–55+CFA.
Secretion of IFN- induced by LCMV infection. Mice were injected 
intravenously with 100 PFU LCMV-WE. Sera were collected 48 h after   
infection  and  analyzed  using  an  IFN-4  ELISA  kit  (Performance  Bio-
medical Laboratories).
Flow cytometry. Antibodies for flow cytometry were as follows: anti-CD4 
(L3T4), anti-CD8 (53–6.7), anti-CD45R/B220 (RA3-6B2), anti-CD11c 
(HL3),  anti-CD19  (1D3),  anti–I-Ab  (AF6-120.1),  anti-CD11b  (M1/70), 
anti-CD45 (30-F11), anti-CD25 (PC61), anti-CD69 (H1.2F3), anti-CD86 
(GL1), anti-CD40 (3/23), anti–IFN- (XMG1.2), and anti–IL-17 (TC11-
18H10; BD). Intracellular cytokine staining was done with the Cytofix/ 
Cytoperm kit (BD). T cell proliferation was assessed by flow cytometry   
using an anti–human Ki67 staining kit (BD) containing anti-Ki67 (B56) and 
the isotype control (MOPC-21). Anti-Foxp3 (FJK-16s) and anti–PDCA-1 
(BST-2, CD317) were obtained from eBioscience. Foxp3 staining was per-
formed with the eBioscience kit.
T cell restimulation assays. 105 mononuclear LN and SC cells were incu-
bated with 105 T cell–depleted splenocytes (Pan T isolation kit; Miltenyi Bio-
tec) for 24 h in complete medium (RPMI and 10% FCS, supplemented with 
penicillin, streptomycin, L-glutamine, sodium pyruvate, and 2-mercaptoetha-
nol) containing 100 µg/ml MOG35–55. GolgiPlug (BD) was added for the final 
4 h. Cells were analyzed by flow cytometry. IL-17, IFN-, IL-4, and IL-10 
were measured in the culture supernatant using a Milliplex Mouse, cytokine 
3plex (Millipore), or a Th1/Th2/Th17 Cytometric Bead Array (BD).
Ag presentation assays. Variable numbers of LN cDCs and pDCs were 
cultured with 105 CD4+ 2D2 T cells in RPMI and 10% FCS in 96-well round-
bottom plates. T cell activation was quantified after 18 h by flow cytometry 
using anti-CD69 antibodies.
In vitro T reg cell induction. 5 × 104 BM pDCs (CD11cintB220+PDCA-1+) 
or BM cDCs (CD11chiB220PDCA-1) were incubated with 10 µM MOG35–55 
and stimulated with 3 µM CpG-A plus 3 µM CpG-B (InvivoGen) or 10 ng/ml 
LPS (Enzo Life Sciences, Inc.), respectively. 105 CD4+ T cells from 2D2 × 
Foxp3-GFP mice were then added to the culture for 96 h.
Cell isolation. CD4+ T cells were purified from LNs using a CD4+ T cell 
purification kit (Miltenyi Biotec). Purified T cells were labeled with CMTMR 
or 10 µM CFSE (Invitrogen) before injection into the tail vein of recipient mice. 
cDCs and pDCs were purified from LNs by cell sorting using a FACSAria 
(BD). Mononuclear cells were isolated from the SC as previously described 
(Katz-Levy et al., 1999). BM pDCs and BM cDCs were generated as follows. 
After red cell lysis, BM cells were cultured for 7 d in complete RPMI me-
dium containing 100 ng/ml of human Flt3L (PeproTech) for pDC generation   
or 20 ng/ml granulocyte-macrophage colony-stimulating factor (PeproTech) 
for cDC generation. pDCs and cDCs were further purified by sorting of 
CD11cintB220+PDCA-1+  cells  and  CD11chiB220PDCA-1  cells,  respec-
tively, using a FACSVantage SE (BD).
Cytokine production by pDCs. BM-pDCs or pDCs purified from LNs 
were incubated for 24 h with CpG type A: ODN 1585 (5-GGGGTCAAC-
GTTGAGGGGGG-3; InvivoGen). IFN-4 was measured in the culture 
supernatants using an IFN-4 ELISA kit (Performance Biomedical Labora-
tories). IL-6 and TNF were measured using a Mouse Inflammation Cyto-
metric Bead Array (BD).
T cells and cDCs (unpublished data). Because the dynamics 
of T cell interactions with APCs are known to contribute to 
the functional outcome T cell stimulation (Hugues et al., 
2006),  an  intriguing  possibility  is  that  brief  contacts  with 
pDCs favor T reg cell development.
MS patients exhibit impaired peripheral T reg cell func-
tions (O’Connor and Anderton, 2008). In addition, pDCs 
exhibiting impaired maturation have been described in MS 
patients (Pashenkov et al., 2001; Stasiolek et al., 2006; Lande 
et al., 2008). This suggests that the mechanism we have un-
covered in the context of EAE may also be relevant for the 
human disease, raising the hope that our findings may pave 
the way for the development of novel therapeutic strategies. 
For instance, the transfer of myelin-Ag–loaded pDCs or ap-
proaches designed to expand and activate pDCs would favor 
the presentation of CNS-derived Ags by pDCs, thus stimu-
lating T reg cell induction by pDCs, and eventually might 
benefit MS patients.
MATERIALS AND METHODS
Mice. All mice had a pure C57BL/6 background and were maintained un-
der SPF conditions. C57BL/6 (CD45.1 or CD45.2) mice were maintained 
in our animal facility. pIII+IV/ (LeibundGut-Landmann et al., 2004), 
MT (Kitamura et al., 1991), H2-Aa/ (Köntgen et al., 1993), OT-II 
(Barnden et al., 1998), 2D2 (Bettelli et al., 2003), and Foxp3-GFP (Skupsky 
et al., 2010) mice have been previously described. All animal husbandry and 
experiments were approved by and performed in accordance with guidelines 
from the animal research committee of the University of Geneva.
BM chimeras. BM from tibia and femurs was recovered by flushing with 
PBS-EDTA, dissociated by repeated passages through a 20-gauge needle, 
and red cells were lysed. 7 × 106 cells were injected intravenously into irradi-
ated (900 rad) recipients. Reconstitution was assessed by analyzing blood 
cells by flow cytometry after 6–8 wk.
EAE experiments. EAE was induced by active immunization with 100 µg 
MOG35–55 (MEVGWYRSPFSRVVHLYRNGK; Biotrend) or 200 µg of re-
combinant mouse MOG (aa 1–121; Urich et al., 2006). Recombinant mouse 
MOG was provided by B. Becher (University Hospital of Zurich, Zurich, 
Switzerland). Mice received subcutaneous injections in both flanks of MOG35–55 
or  recombinant  MOG  emulsified  in  incomplete  Freund  adjuvant  (Sigma- 
Aldrich) supplemented with 500 µg/ml Mycobacterium tuberculosis (BD). Mice 
were also injected with 100 ng pertussis toxin (Sigma-Aldrich) into the tail vein 
at days 0 and 2. EAE symptoms were scored as follows: 1, flaccid tail; 2, im-
paired righting reflex and hind limb weakness; 3, partial hind limb paralysis;   
4, complete hind limb paralysis; 5, hind limb paralysis with partial fore limb pa-
ralysis; 6, moribund. Intravenous injections with 5 or 50 ng IFN- (Miltenyi 
Biotec) were done on the same day as induction of EAE. Adoptive transfer EAE   
experiments with encephalitogenic CD4+ T cells from chimeric mice were per-
formed as follows. Mice were immunized with MOG35–55+CFA on day 0, re-
challenged with MOG35–55+CFA on day 7, and dLNs and spleens were harvested 
on day 11. CD4+ T cells were purified and incubated for 3 d with 10 µg/ml 
MOG35–55 and irradiated T cell–depleted splenocytes from naive mice. Live 
cells were isolated using Lympholyte M gradient (Cedarlane Laboratories) and 
5 × 106 cells were injected into the tail vein of recipient mice.
Adoptive  transfer  EAE  experiments  with  encephalitogenic  CD4+  
T cells from 2D2 mice were performed as follows. LN cells from 2D2 mice 
were incubated for 5 d with 10 µg/ml MOG35–55 in the presence of 2.5 ng/ml 
of recombinant mouse IL-18 (MBL). CD4+ T cells were purified, live   
cells were isolated using Lympholyte M gradient, and 5 × 106 cells were in-
jected into the tail vein of recipient mice. EAE symptoms in adoptive trans-
ferred EAE were scored as for EAE induced by immunization.1904 MHCII-mediated Ag presentation by pDC inhibits EAE | Irla et al.
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formaldehyde  (4%)  and  embedded  in  paraffin.  Paraffin  sections  were 
stained with hematoxylin & eosin and Luxol fast blue. Frozen SCs were 
perfused with saline buffer and embedded in OCT (Sakura). Sections 
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script II reverse transcription (Invitrogen). PCR was performed with the 
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Statistics. Statistical significance was assessed by the two-tailed Student’s t 
test, except for incidence of clinical EAE, for which statistical significance 
was assessed by the 2 test.
Online supplemental material. Fig. S1 shows the differential regulation 
of the gene encoding the MHC CIITA in cDCs, pDCs, and B cells. Fig. S2 
shows a normal cytokine production by pIII+IV/ pDCs. Fig. S3 shows 
that EAE exacerbation of in pIII+IV/:WT chimeras is a consequence of 
deficient MOG presentation rather than altered IFN- production by pDCs. 
Fig. S4 compares EAE histopathology in mice lacking or not MHCII ex-
pression by pDCs. Fig. S5 illustrates accentuated CNS inflammation during 
EAE in mice lacking MHCII expression by pDCs. Fig. S6 shows that the 
up-regulation of MHCII expression by activated microglia occurs normally 
during EAE in pIII+IV/:WT chimeras. Fig. S7 shows a reduced T reg cell 
proliferation in the spleen of pIII+IV/:WT chimeras during EAE. Table S1 
shows that MHCII expression by pDCs induces the expansion of protective 
T reg cells. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20092627/DC1.
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